Bicara Therapeutics Inc.

Clinical-stage oncology biotech developing bifunctional antibody therapeutics that combine tumor targeting with TGF-β blockade in the tumor microenvironment. Lead asset ficerafusp alfa (BCA101) is a bifunctional EGFR x TGF-β trap in a Phase 2/3 pivotal trial (FORTIFI-HN01) in 1L HPV-negative HNSCC, with FDA Breakthrough Therapy designation in combination with pembrolizumab.